既对艾曲泊帕又对罗米司亭耐药的免疫性血小板减少症。
The problem of immune thrombocytopenia refractory to both eltrombopag and romiplostim.
机构信息
Division of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Department of Hematology/Oncology, University Children's Hospital Basel, Basel, Switzerland.
出版信息
Br J Haematol. 2024 Apr;204(4):1143-1145. doi: 10.1111/bjh.19327. Epub 2024 Feb 6.
Immune thrombocytopenia refractory to multiple thrombopoietin receptor agonists remains a challenging clinical problem. This commentary discusses and contextualizes the recent report on this entity from Moulis and colleagues, and how to move forward with these patients. Commentary on: Moulis et al. Difficult-to-treat primary immune thrombocytopenia in adults: Prevalence and burden. Results from the CARMEN-France Registry. Br J Haematol 2024;204:1476-1482.
对多种血小板生成素受体激动剂难治的免疫性血小板减少症仍然是一个具有挑战性的临床问题。本评论讨论并阐述了 Moulis 等人最近关于该疾病的报告，以及如何处理这些患者。评论：Moulis 等人。成人难治性原发性免疫性血小板减少症：患病率和负担。来自法国 CARMEN 登记处的结果。英国血液学杂志 2024；204:1476-1482。
Zotero 插件